Trial Profile
A Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib (ONO/GS-4059) in Combination With Other Targeted Anti-cancer Therapies in Subjects With B-cell Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs Tirabrutinib (Primary) ; Entospletinib; Idelalisib; Obinutuzumab
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 30 Nov 2020 Status changed from recruiting to active, no longer recruiting.
- 14 Sep 2020 Patients from this study were consented and included in a in vitro and in vivo analysis of Btk and Syk inhibitors on platelet functions, according to results published in the Journal of Thrombosis and Haemostasis
- 12 Aug 2020 Planned number of patients changed from 368 to 376.